Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

The Nutrition Center warns people who want to lose weight not to take medication too lightly. “It may seem easy, but do not ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Concerns over new age weight loss, diabetes drugs ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant ...